Khi được bạn cho phép, chúng tôi sử dụng phân tích giới hạn, chú trọng quyền riêng tư để hiểu hành trình nghiên cứu nào hiệu quả. Chúng tôi không dùng trình theo dõi quảng cáo hoặc ghi lại phiên. Bạn có thể thay đổi lựa chọn này trong Tùy chọn. Đọc Chính sách quyền riêng tư.
Quote this valuation with its source: Fair value, Potential value and the price at analysis.
FAQ
ILMN — frequently asked questions
Is Illumina, Inc. overvalued?
In our latest published analysis dated 2026-10-22, ILMN looks meaningfully overvalued. The price recorded at analysis is 259 USD versus our fair value of 120 USD; the high endpoint is presented separately as potential value of 147 USD. That implies roughly 53.9% downside to fair value at that date.
Our latest published report, analyzed 2026-10-22, gives ILMN a fair value of 120 USD and a potential value of 147 USD. The conclusion is triangulated across multiple valuation models and weighted by reliability for Illumina, Inc.'s archetype; it is a dated research output, not a live price.
Should I buy ILMN now?
Our latest published rating for ILMN, analyzed 2026-10-22, is Sell. Illumina, Inc. looks meaningfully overvalued at the analysis-date price of 259 USD versus fair value of 120 USD; potential value is 147 USD. This is research for educational purposes, not personalized investment advice.
What are the biggest risks for ILMN?
The dedicated bear-case section in our report analyzed 2026-10-22 documents Illumina, Inc.'s material risks, evidence, thresholds, and thesis-invalidation conditions. Scenario-specific explanations remain in that section so the report does not repeat or decontextualize them elsewhere.
What is ILMN's rating?
Our latest published rating for ILMN, analyzed 2026-10-22, is Sell, with a published moat assessment of 9/10 (Wide). It reflects our fair value of 120 USD, the potential value of 147 USD, and the price recorded at analysis (259 USD).
Báo cáo này chưa được dịch. Hãy làm mới sau vài phút khi hàng đợi dịch xử lý xong.
§1 Tóm tắt điều hànhEN
Câu trả lời trong 30 giâySell
Giá so với giá trị
Giá
$259.19
Giá trị hợp lý
$119.53
Giá trị tiềm năng
$146.73
Tính đến
2026-10-22
Vì sao luận điểm có thể đúng
Accelerated clinical diagnostic adoption in oncology minimal residual disease (MRD) testing and whole-genome rare disease screening driving NovaSeq X consumable pull-through well above mid-teens expectations.
Điều gì sẽ thay đổi quan điểm của chúng tôi
A prolonged contraction in academic and government research funding combined with persistent high-bandwidth memory component cost inflation.
Illumina is rated Sell with Fair value of $119.53 compared to $259.19, reflecting -53.9% upside.
Illumina commands a Wide economic moat underpinned by massive clinical switching costs and proprietary sequencing-by-synthesis (SBS) intellectual property. Clinical customers are expanding their installed base of NovaSeq X instruments to support expanding clinical test volumes, driving mid-teens clinical consumables growth guidance for FY2026. Following the divestiture of GRAIL, core operating profitability has rebounded, with GAAP operating income reaching $807M in FY2025 and FY2026 non-GAAP operating margin guided to 23.4%-23.6%. of $1,079M in FY2025 yielded $931M in .
Despite these solid operational fundamentals, the stock exhibits an extreme valuation disconnect. At $259.19, ILMN trades at 40.32x forward earnings, pricing in aggressive multi-year growth acceleration that conflicts with low single-digit sequencing instrument growth and mid-to-high single-digit contraction in research consumables. Reverse DCF analysis demonstrates that current pricing requires a 19.44% 10-year earnings CAGR, far above the realistic 11.04% rate supported by business economics. Our multi-model intrinsic fair value midpoint of $119.53 sits 46.38% below the present-value equivalent of the consensus 12-month target of $222.94, establishing a clear Sell recommendation.2,4,5
High Customer Switching Costs in Clinical Workflows
Clinical diagnostic customers develop validated laboratory developed tests (LDTs) and IVD workflows around Illumina hardware and proprietary sequencing chemistry, creating immense switching costs and multi-year consumable pull-through.5
Proprietary Intellectual Property and Sequencing Chemistry
Illumina maintains extensive intellectual property protecting its proprietary sequencing-by-synthesis (SBS) technology and optical detection systems, supporting consolidated gross profit of $2,870M on $4,343M revenue (66.1% gross margin) in FY2025.5,7
Installed Base Scale and Ecosystem Integration
A massive global installed base of NovaSeq X and benchtop instruments creates strong platform network effects and workflow standardization across major hospital systems and commercial laboratories.5
Khuyến nghị của hãng
Sell. Illumina is an exceptional business trading at a speculative valuation. While the company's Wide economic moat and clinical sequencing expansion remain fully intact, the market price of $259.19 trades at a 116.84% premium to our intrinsic fair value midpoint of $119.53. With the equity discounting an aggressive 19.44% multi-year growth rate against management's 6.5% modeled FY2026 growth, the risk/reward profile is deeply skewed to the downside.1
Tổng quan công ty
Illumina, Inc. is a global provider of life science tools and integrated systems for large-scale analysis of genetic variation and biological function. The company develops, manufactures, and commercializes next-generation sequencing (NGS) and array-based technologies serving customers across clinical, academic, and applied end-markets. Key platforms include the high-throughput NovaSeq X series, alongside mid-throughput NextSeq and benchtop MiSeq instruments.
In FY2025, Illumina generated $4,343M in consolidated net revenue. Geographically, the business is anchored by the United States, which contributed $2,243M (51.6% of sales), within the broader Americas region at $2,406M (55.4%). Europe contributed $1,264M (29.1%), Asia-Pacific, Middle East, and Africa (APMEA) delivered $430M (9.9%), and Greater China generated $243M (5.6%). Following the completed spin-off of GRAIL, Illumina operates as a streamlined pure-play genomic sequencing platform.
§2 Kịch bản tiêu cựcEN
A compounding downside stress test models simultaneous academic grant freezes, persistent high-bandwidth memory component inflation, and regulatory displacement in Greater China. In this environment, research consumables contract by double digits, operating margins compress toward 21.0%, and total top-line revenue growth stalls below 4.0%. Under these operating pressures, intrinsic valuation contracts toward the downside valuation floor of $91.84. At $259.19, long investors face severe, unhedged downside vulnerability without an adequate margin of safety.
Under the Bear scenario, persistent academic research budget contractions suppress consumable utilization while high-bandwidth memory input inflation and China revenue contraction constrain operating margins to approximately 21.0%. Five-year revenue CAGR slows toward low single digits as clinical adoption fails to fully offset broader research lab headwinds.
Các cách luận điểm này có thể đổ vỡ
Persistent Memory Cost Inflation and Research Consumable Margin Compression
Unanticipated spikes in high-bandwidth memory and freight expenses combined with mid-to-high single-digit declines in research consumables compress operating margin below 20.5% (a 300 bps shock against the 23.5% baseline guidance), driving an 18.5% fair value impairment.5
FV impact
0%
Operating margin 3 points lower throughout
Trigger
Within 12 months
Tín hiệu cảnh báo sớm cần theo dõi
Năm diễn biến có thể làm suy yếu luận điểm đầu tư của chúng tôi.
01
Research and Applied Consumables Growth
Signals deep structural funding contraction in academic and government laboratories that overwhelms clinical expansion.
Hiện tại:Mid-to-high single-digit decline in FY2026
Cảnh báo nếuDecline exceeding 12% YoY for two consecutive quarters
Indicates failure to offset component inflation in memory and GPUs and severe loss of operating expense .
§3 Lợi thế cạnh tranhEN
Wide
Illumina possesses a Wide economic moat anchored by massive switching costs and proprietary intellectual property in next-generation sequencing (NGS). In clinical diagnostic settings—including oncology profiling, non-invasive prenatal testing (NIPT), and rare disease genetics—customers validate laboratory procedures, regulatory compliance filings, and bioinformatics pipelines specifically around Illumina's sequencing-by-synthesis technology. Replacing an installed sequencing fleet incurs immense re-validation costs, regulatory re-filing burdens, and retraining hurdles, locking in customers for the multi-year lifecycle of each instrument.
This customer captivity transforms instrument placements into recurring, high-margin reagent consumption. Product gross profit was $2,870M on $4,343M in FY2025 revenue, and non-GAAP gross margin reached 68.2% in Q2 2026. In clinical end-markets, management projects mid-teens revenue growth for FY2026, demonstrating that high-value diagnostic applications continue to deepen Illumina's moat outside of Greater China, where regulatory sanctions have restricted market access ($243M in FY2025 revenue).
Lợi nhuận kinh tế
Illumina generates sustainable economic profit with an ROIC of 15.08% exceeding its weighted average cost of capital (WACC) of 9.90% and cost of equity of 10.26% by 518 bps. Following the divestment of GRAIL, GAAP operating income rebounded to $807M in FY2025 on $4,343M in consolidated revenue, supporting excess returns over a 15-year competitive advantage horizon.2,7
9/ 10
Wide
Sources of advantage
01High Customer Switching Costs in Clinical Workflows — Clinical diagnostic customers develop validated laboratory developed tests (LDTs) and IVD workflows around Illumina hardware and proprietary sequencing chemistry, creating immense switching costs and multi-year consumable pull-through.Wide
02Proprietary Intellectual Property and Sequencing Chemistry — Illumina maintains extensive intellectual property protecting its proprietary sequencing-by-synthesis (SBS) technology and optical detection systems, supporting consolidated gross profit of $2,870M on $4,343M revenue (66.1% gross margin) in FY2025.
Mối đe dọa đã biết với lợi thế cạnh tranh
Mối đe dọa
Mức độ
Mốc thời gian
Giảm thiểu
Academic and Government Research Laboratory Funding Contraction
medium
12-18 months
Expanding commercial exposure in clinical oncology and genetic disease diagnostics, where demand is nondiscretionary and growing mid-teens.5
The highlighted cell is Fair value when every assumption sits at its base level ($119.53). Each row and column shows what Fair value becomes when one assumption moves.
The modal base path reflects management's FY2026 guidance for reported revenue and operating margin. Clinical consumables expansion at mid-teens offsets mid-to-high single-digit research declines. This trajectory generates Fair value of $119.53, implying -53.9% return relative to $259.19.5
Maintain Sell; Maintain capital discipline and use any post-earnings liquidity strength to continue liquidating or trimming overvalued equity positions.
Even a material quarterly beat does not resolve the substantial valuation disconnect where the stock trades at 40.32x forward earnings and a 116.84% premium to intrinsic fair value.
Đúng kỳ vọng
Maintain Sell; Maintain existing risk management constraints and deploy zero fresh capital into the equity.
Kích hoạt: Quarterly revenue within $1.14B-$1.16B and non-GAAP diluted EPS within $1.33-$1.385
Meeting guidance confirms the modeled financial path ($4.60B-$4.64B revenue, 23.4%-23.6% operating margin) without bridging the valuation gulf to intrinsic worth of $119.53.
Hụt
Maintain Sell; Re-evaluate downside stop-loss thresholds and ensure no unhedged long exposure remains in institutional portfolios.
High earnings quality. FY2025 operating cash flow of $1,079M represented 126.9% of GAAP net income of $850M, generating $931M in free cash flow. Non-GAAP adjustments in Q2 2026 were routine and clean, consisting primarily of acquisition-related intangible asset amortization ($18M) and ERP transformation implementation expenses ($4M).6,7
Xu hướng dự báo
Consensus revisions remained flat across FY2026 and FY2027 following the Q2 2026 financial release. Sell-side consensus expects FY2026 revenue of $4,624M and diluted EPS of $5.36, and FY2027 revenue of $4,923M and diluted EPS of $6.13.1
Chỉ số cần theo dõi trước khi công bố
01
Chỉ số:
Clinical Sequencing Consumables Growth
Hiện tạiManagement projects mid-teens growth in clinical consumables for FY2026.
Vì sao quan trọng
Tests whether clinical oncology and rare disease testing can outpace research lab headwinds.5
Illumina exhibits strong cash generation. FY2025 operating cash flow reached $1,079M, funding $148M in capital expenditures to generate $931M in free cash flow. In Q2 2026, cash flow from operations was $201M and free cash flow was $162M. Operating cash flow conversion consistently exceeds 100% of GAAP net income ($850M in FY2025), validating the high cash quality of core sequencing operations.6,7
Phân bổ vốn
Illumina exercises conservative capital allocation following the GRAIL separation. Balance sheet cash and short-term investments totaled $1,168M ($1,040M cash plus $128M short-term investments) as of June 28, 2026, against total term debt of $2,527M ($500M current portion plus $1,491M and accrued liabilities). remain modest at $148M in FY2025 and $39M in Q2 2026, absorbing approximately 18% of NOPAT and leaving ample organic for balance sheet de-leveraging.
GAAP operating profitability has recovered to $807M in FY2025 from negative levels in FY2024 (-19.05% margin), with non-GAAP operating margin guided to expand to 23.4%-23.6% in FY2026. ROIC of 15.08% confirms robust economic value creation above the cost of capital.
Product revenue reached $982M in Q2 2026, driven by mid-single-digit sequencing consumables growth while sequencing instruments grew low single digits.
Expanding consumables mix elevates non-GAAP gross margin to 68.2% and reduces top-line cyclicality.
Phân tích báo cáo kết quả kinh doanhQuy mô kinh doanh chuyển thành lợi nhuận báo cáo như thế nào.30 thg 6, 2026
StockMarketAgent.AI
Doanh thu1,2 T US$Giá vốn doanh thu−389 Tr US$Lợi nhuận gộp770 Tr US$Chi phí hoạt động−525 Tr US$Lợi nhuận hoạt động245 Tr US$Các khoản ngoài hoạt động và thuế−38 Tr US$Lợi nhuận ròng207 Tr US$
Dữ liệu lịch sử tài chính
Doanh thu
1.159.000.000 US$
Giá vốn doanh thu
389.000.000 US$
Lợi nhuận gộp
770.000.000 US$
Chi phí hoạt động
525.000.000 US$
Lợi nhuận hoạt động
245.000.000 US$
Các khoản ngoài hoạt động và thuế
-38.000.000 US$
Lợi nhuận ròng
207.000.000 US$
Tổng quan bảng cân đối kế toánCách tài sản đã báo cáo được nắm giữ và tài trợ trong kỳ đã chọn.
StockMarketAgent.AI
Cơ cấu tài sảnNguồn tài trợ
Tổng tài sản6,6 T US$Tiền mặt1,4 T US$Tài sản ngắn hạn3,3 T US$Tổng nợ phải trả3,9 T US$Nợ ngắn hạn1,6 T US$Vốn chủ sở hữu2,7 T US$
Dữ liệu phân tích bảng cân đối kế toán
Tổng tài sản
6.644.000.000 US$
Tiền mặt
1.418.000.000 US$
Tài sản ngắn hạn
3.289.000.000 US$
Tổng nợ phải trả
3.921.000.000 US$
Nợ ngắn hạn
1.585.000.000 US$
Vốn chủ sở hữu
2.723.000.000 US$
Cầu nối dòng tiềnDòng tiền từ hoạt động chuyển thành dòng tiền tự do như thế nào trong FY2025.
StockMarketAgent.AI
Đối chiếu dòng tiền hoạt động
Lợi nhuận ròng850 Tr US$Khấu hao và phân bổ+270 Tr US$Thù lao bằng cổ phiếu+275 Tr US$Điều chỉnh hoạt động khác−316 Tr US$Dòng tiền hoạt động1,1 T US$
Đối chiếu tiền đầu kỳ đến cuối kỳ
Tiền đầu kỳ1,1 T US$Dòng tiền hoạt động+1,1 T US$Dòng tiền đầu tư−55 Tr US$Dòng tiền tài chính−744 Tr US$Ảnh hưởng tỷ giá+11 Tr US$Tiền cuối kỳ1,4 T US$
1,1 T US$ − 148 Tr US$Dòng tiền tự do 931 Tr US$
Dữ liệu cầu nối dòng tiền
Lợi nhuận ròng
850.000.000 US$
Dòng tiền vào từ hoạt động
1.395.000.000 US$
Khấu hao và phân bổ
270.000.000 US$
Thù lao bằng cổ phiếu
275.000.000 US$
Dòng tiền hoạt động
1.079.000.000 US$
Dòng tiền ra từ hoạt động
316.000.000 US$
Tiền sẵn có
2.217.000.000 US$
Tiền đầu kỳ
1.127.000.000 US$
Ảnh hưởng tỷ giá
11.000.000 US$
Dòng tiền ra từ đầu tư
55.000.000 US$
Dòng tiền ra từ tài chính
744.000.000 US$
Mua lại cổ phiếu
742.000.000 US$
Hoàn trả nợ ròng
5.000.000 US$
Tiền cuối kỳ
1.418.000.000 US$
Dòng tiền đầu tư
-55.000.000 US$
Dòng tiền tài chính
-744.000.000 US$
Doanh thu theo phân khúc hoạt độngTỷ trọng trong tổng doanh thu của 2024-12-29.
4,4 T US$Tổng doanh thu
Doanh thu theo phân khúc hoạt độngTỷ trọng
Core Illumina4,3 T US$99,1%−2,4% so với cùng kỳ
GRAILInc.55 Tr US$1,3%−40,9% so với cùng kỳ
Nguồn: SEC EDGAR · Nộp ngày 2026-02-12 · SEC EDGAR
Dữ liệu cơ cấu doanh thu: Doanh thu theo phân khúc hoạt động
Doanh thu theo phân khúc hoạt động
Doanh thu
Tỷ trọng
so với cùng kỳ
Core Illumina
4,3 T US$
99,1%
-2,4%
GRAILInc.
55 Tr US$
1,3%
-40,9%
Doanh thu và lợi nhuậnQuy mô kinh doanh chuyển thành lợi nhuận báo cáo như thế nào.
Tiền mặt và nợThanh khoản sẵn có so với tổng dư nợ.
Tạo dòng tiềnDòng tiền hoạt động so với dòng tiền tự do.
Khả năng sinh lờiDiễn biến biên gộp, biên hoạt động và biên ròng.
Dữ liệu tài chính tại thời điểm được dùng trong phân tích ngày 2026-10-22.
Dữ liệu lịch sử tài chính
Kỳ
Doanh thu
EBITDA
Lợi nhuận ròng
Dòng tiền hoạt động
Dòng tiền tự do
Capex
Khấu hao và phân bổ
Thù lao bằng cổ phiếu
Mua lại cổ phiếu
Cổ tức đã trả
Phát hành nợ ròng
Dòng tiền đầu tư
Dòng tiền tài chính
Tiền đầu kỳ
Tiền cuối kỳ
Tiền mặt và đầu tư
Tổng nợ
Biên hoạt động
ROIC
WACC
Chênh lệch ROIC−WACC
2017-01-01
2,4 T US$
735 Tr US$
463 Tr US$
779 Tr US$
519 Tr US$
260 Tr US$
141 Tr US$
129 Tr US$
249 Tr US$
11,6 Tr US$
—
-515 Tr US$
-296 Tr US$
—
735 Tr US$
1,6 T US$
1 T US$
24,5%
—
7,1%
—
2017-12-31
2,8 T US$
762 Tr US$
726 Tr US$
875 Tr US$
565 Tr US$
310 Tr US$
156 Tr US$
164 Tr US$
251 Tr US$
5 Tr US$
—
-214 Tr US$
-176 Tr US$
735 Tr US$
1,2 T US$
2,1 T US$
1,2 T US$
22,0%
—
6,2%
—
2018-12-30
3,3 T US$
1,1 T US$
826 Tr US$
1,1 T US$
846 Tr US$
296 Tr US$
179 Tr US$
193 Tr US$
201 Tr US$
735 Tr US$
—
-1,8 T US$
594 Tr US$
1,2 T US$
1,1 T US$
3,5 T US$
838 Tr US$
26,5%
—
7,0%
—
2019-12-29
3,5 T US$
1,2 T US$
1 T US$
1,1 T US$
842 Tr US$
209 Tr US$
188 Tr US$
194 Tr US$
324 Tr US$
—
—
745 Tr US$
-897 Tr US$
1,1 T US$
2 T US$
3,4 T US$
1,9 T US$
27,8%
—
6,0%
—
2021-01-03
3,2 T US$
580 Tr US$
656 Tr US$
1,1 T US$
891 Tr US$
189 Tr US$
187 Tr US$
194 Tr US$
736 Tr US$
—
—
-554 Tr US$
-766 Tr US$
2 T US$
1,8 T US$
3,5 T US$
1,9 T US$
17,9%
—
4,6%
—
2022-01-02
4,5 T US$
128 Tr US$
762 Tr US$
545 Tr US$
337 Tr US$
208 Tr US$
251 Tr US$
754 Tr US$
0 US$
511 Tr US$
—
-1,1 T US$
-51 Tr US$
1,8 T US$
1,2 T US$
1,3 T US$
2,5 T US$
-2,7%
—
4,9%
—
2023-01-01
4,6 T US$
-3,8 T US$
-4,4 T US$
392 Tr US$
106 Tr US$
286 Tr US$
394 Tr US$
366 Tr US$
0 US$
937 Tr US$
991 Tr US$
-591 Tr US$
1 T US$
1,2 T US$
2 T US$
2 T US$
3,6 T US$
-91,2%
—
—
—
2023-12-31
4,5 T US$
-1,1 T US$
-1,2 T US$
478 Tr US$
283 Tr US$
195 Tr US$
432 Tr US$
380 Tr US$
0 US$
—
-1,2 T US$
-231 Tr US$
-1,2 T US$
2 T US$
1 T US$
1,1 T US$
2,3 T US$
-23,7%
—
7,5%
—
2024-12-29
4,4 T US$
-725 Tr US$
-1,2 T US$
837 Tr US$
709 Tr US$
128 Tr US$
354 Tr US$
370 Tr US$
116 Tr US$
—
491 Tr US$
-178 Tr US$
-570 Tr US$
1 T US$
1,1 T US$
1,2 T US$
2,6 T US$
-19,1%
—
—
—
2025-12-28
4,3 T US$
1,5 T US$
850 Tr US$
1,1 T US$
931 Tr US$
148 Tr US$
270 Tr US$
275 Tr US$
742 Tr US$
—
-5 Tr US$
-55 Tr US$
-744 Tr US$
1,1 T US$
1,4 T US$
1,6 T US$
2,6 T US$
18,6%
—
8,8%
—
§9 So sánh định giá với các doanh nghiệp cùng ngành
Giá trị hợp lýReport-date price
Illumina, Inc.ILMN
Giá / giá trị hợp lý
Giá trị hợp lý119,53 US$Report-date price259,19 US$
Ngày đánh giá
Hào kinh tếWide
Bảng điểm đầu tư64 / 100
IDEXX Laboratories Inc.IDXX
Giá / giá trị hợp lý
Giá trị hợp lý342,77 US$Report-date price565,45 US$
Ngày đánh giá
Hào kinh tếWide
Bảng điểm đầu tư67 / 100
IQVIA Holdings Inc.IQV
Giá / giá trị hợp lý
Giá trị hợp lý215,19 US$Report-date price258,21 US$
Ngày đánh giá
Hào kinh tếNarrow
Bảng điểm đầu tư51 / 100
Illumina, Inc.ILMN
Giá / giá trị hợp lý
Giá trị hợp lý119,53 US$Report-date price259,19 US$
Illumina, Inc. (ILMN) trades at 40.3x forward earnings against a peer median of 22.4x. Its EV/EBITDA of 38.2x compares with a peer median of 22.4x. The comparison uses 4 peers: IDEXX Laboratories Inc., IQVIA Holdings Inc., Agilent Technologies Inc. and Labcorp Holdings Inc., as of 2026-10-22.
§10 Ngành và chu kỳEN
Pha chu kỳ
Contraction
The life sciences tools industry benchmark exhibits disciplined capital intensity, with industry capex-to-revenue at 4.5% and capex-to-depreciation at 0.8. Illumina's capex was $148M on $4,343M revenue (3.41%) in FY2025 against depreciation of $270M (capex/depreciation of 0.55). Capex was $39M in Q2 2026. Industry capacity and supplier lead-time data are unavailable, meaning this capital cycle assessment is demand-led and evidence-limited.7
Chu kỳ tăng giá
In an expansionary upcycle, synchronized recovery in biopharma R&D funding and academic research grants accelerates NovaSeq X placements above low single digits, driving double-digit expansion across clinical and research sequencing consumables.
Chu kỳ giảm giá
In a severe tools downcycle, prolonged academic and government grant constraints deepen research consumable contractions beyond mid-to-high single digits, clinical instrument purchasing approvals face hospital budget scrutiny, and consolidated revenue growth decelerates toward low single digits.
Xu hướng dài hạn
Xu hướng
Tác động
Ghi chú
Clinical Genomics and Multiomics Expansion
positive
Next-generation sequencing is transitioning into standard-of-care clinical diagnostic protocols across oncology and rare disease, supporting mid-teens clinical market growth.
Academic and Government Research Funding Constraints
negative
Austerity in government research grants and university endowments drives mid-to-high single-digit declines in research and applied consumables.
Geopolitical Bifurcation in Analytical Instrumentation
Định vị
Illumina maintains a highly defended demand position in clinical oncology and genetic testing, anchored by $2,243M in United States revenue (51.6% of FY2025 net sales). This non-discretionary clinical diagnostic base buffers consolidated revenue against biopharma capex pauses and academic funding austerity, allowing Illumina to navigate industry capital cycles more resiliently than pure-play research tools peers.8
§11 Quản lý vị thếEN
Quy mô vị thế
0%
A 0% allocation is warranted due to extreme valuation excess. The equity trades at $259.19, representing a 116.84% premium to our intrinsic fair value midpoint of $119.53 and a 76.64% premium even to the high-end Bull case of $146.73. Risk/reward is entirely uncompensated for long investors.4
Rủi ro
Capital preservation is paramount. Given the 116.84% premium to intrinsic fair value and forward P/E of 40.32x, long exposure entails severe downside vulnerability if quarterly revenue or operating marginguidance falls short. Portfolios should reallocate capital to life sciences tools peers offering realistic valuations.
Đợt vào lệnh
Mức
Hành động
Lý do
$119.53
Valuation review checkpoint
Aligns price with intrinsic fair value midpoint of $119.53, eliminating the speculative valuation premium.
At 40.32x forward earnings and a 116.84% premium to intrinsic fair value, the equity prices in a 19.44% 10-year growth rate that is detached from management guidance and market reality.2,4
Fundamental Quality vs Price
Avoid
Although Illumina possesses a Wide moat and robust free cash flow generation ($931M in FY2025), high business quality cannot justify paying over double the business's intrinsic worth.6
Risk/Reward Asymmetry
Avoid
Even under an optimistic Bull case where clinical growth accelerates and operating margins reach 26%, fair value reaches only $146.73, which remains 43.4% below current trading prices of $259.19.4
§14 Khuyến nghị cuối cùngEN
Hành động
Bán
We recommend a Sell rating on Illumina, Inc. with Fair value of $119.53 against the share price of $259.19, reflecting -53.9% upside. While Illumina commands a wide economic moat in clinical genetic sequencing, shares trade well above intrinsic worth.
The stock trades at 40.32x forward earnings, pricing in aggressive growth acceleration that conflicts with low single-digit instrument placement growth and research consumables contraction. Investors should exit long positions and reallocate capital elsewhere.
§15Your notes
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Private notes
Visible only to you. Synced to this device.
0 chars
Sources
The records this analysis drew on, as they stood when it was run.
Not every cited input appears here: internal calculations and intermediate model outputs have no external record, and some citations could not be matched to one.
Multiple De-Rating on Structural Deceleration in Academic Sequencing
If FY2027 revenue fails to achieve high single-digit growth due to prolonged academic lab funding contraction, market expectations de-rate the terminal P/E multiple by 20% from 24.0x to 19.2x, aligning valuation with peers like IQVIA at 19.2x forward P/E, generating a 20.0% fair value contraction.5
FV impact
-8.5%
Terminal multiple 20% lower
Trigger
Within 18 months
Clinical Adoption Stagnation and Severe Research Lab Disinvestment
Sequencing instruments growth stagnates near low single digits and research consumables continue contracting, driving 5-year revenue growth 500 bps below the modeled 6.5%-7.5% trajectory, triggering a 27.5% fair value decline.1,5
FV impact
-2.4%
Revenue and EPS growth 5 points lower for five years
03Installed Base Scale and Ecosystem Integration — A massive global installed base of NovaSeq X and benchtop instruments creates strong platform network effects and workflow standardization across major hospital systems and commercial laboratories.Moderate
Geopolitical Sanctions and Domestic Substitution in Greater China
medium
Ongoing
Diversifying geographic mix toward the Americas ($2,406M FY2025) and Europe ($1,264M FY2025), isolating China to 5.6% ($243M) of total sales.8
Hardware Input Cost Spikes in Memory and GPUs
low
6-12 months
Securing forward component inventory buffers and driving manufacturing operational efficiencies.5
In the Bull case, clinical sequencing expands rapidly across oncology and rare disease diagnostics, driving mid-teens clinical consumables growth and enabling FY2027 revenue to reach high single digits. Operating margins expand via high consumable pull-through, supporting Potential value of $146.73. Notably, even this optimistic outcome remains well below $259.19.5
Vì sao quan trọng
Confirms whether operational discipline offsets memory and freight cost inflation.5
03
Chỉ số:
NovaSeq X Instrument Placement Pace
Hiện tạiFull-year sequencing instrument growth guided to low single digits.
Vì sao quan trọng
Active instrument additions drive the high-margin consumable replenishment stream in subsequent years.5
04
Chỉ số:
Research & Applied Consumables Run-Rate
Hiện tạiGuided to decline mid to high single digits in FY2026.
Vì sao quan trọng
Measures the extent of academic and government lab funding contraction.5
05
Chỉ số:
US Clinical Demand Concentration
Hiện tạiGenerated $2,243M in FY2025, or 51.6% of consolidated revenue.
Vì sao quan trọng
US diagnostic adoption provides the primary demand anchor insulating against China geopolitical headwinds.8
